Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Fresenius Biotech GmbH
Femme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Estudio de fase II del anticuerpo trifuncional anti-HER-2/neu x anti-CD3 ertumaxomab en pacientes con cáncer de mama avanzado o metastásico resistente al tratamiento hormonal que expresa HER2/neu 1+ o 2 Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer
To demonstrate clinical efficacy of the investigational trifunctional antibody (ertumaxomab) for the treatment of hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cancer patients with malignant ascites
- Determination of systemic exposure of catumaxomab during and after four intraperitoneal infusions with increasing doses - Characterization of pharmacokinetics of catumaxomab after the second, the th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Prospective, randomized, multi-center, open label phase III study to evaluate the efficacy and safety of immunosuppression following a heart-beating cadaveric renal transplantation based on the use of rabbit anti-T-lymphocyte serum, tacrolimus and mycophenolate, free of concomitant corticosteroids from the start of immunosuppression
The primary objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard tr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Two-arm, randomized (2:1), open-label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites using paracentesis plus the tri-functional antibody removab (anti-EpCAM x anti-CD3) versus paracentesis alone
To demonstrate the superiority of a treatment with paracentesis plus removab over a treatment with paracentesis alone in terms of puncture free survival
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Phase II study for repeated dosing of the trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with HER-2/neu 1+ or 2+/FISH negative expressing advanced or metastatic breast cancer (stage IIIb/IV) progressing after endocrine treatment
The primary objective of the study is to demonstrate clinical efficacy of the investigational trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or 2+ expressing...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia
Phase I, Dose escalation • determination of the maximum tolerated dose (MTD) of FBTA05 in patients with relapsed or refractory chronic lymphocytic leukemia (B-CLL). Phase II, Efficacy • evaluation of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Treatment of Graves’ Orbitopathy (GO) with ATG-Fresenius: A prospective, randomized, open, controlled phase II study to assess the efficacy and safety of an add-on ATG-Fresenius treatment versus a standard steroid treatment
The primary objective of the study is to investigate whether add-on treatment of ATG-Fresenius S to standard steroid therapy has a beneficial effect on response to therapy defined as Clinical Activity...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme
Entre 18 ans
et 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Fresenius IV-ERT-BC-03 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par ertumaxomab chez des patientes ayant un cancer du sein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Phase II study for repeated dosing of the trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with HER-2/neu 1+ or 2+/FISH negative expressing advanced or metastatic br...
Pays
France
Organes
Sein
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxies with cyclosporine A and Methotrexate with additional pretransplant ATG-Fresenius S
Valutare l'efficacia di ATG-Fresenius S in aggiunta alla terapia standard (ciclosporina A/Metotressato) nel trattamento del fallimento precoce della terapia definito come il verificarsi della malattia...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Fresenius Biotech GmbH
MAJ Il y a 5 ans
Multicenter, open-label and randomized phase II study to evaluate safety and efficacy of the tri-functional bispecific antibody catumaxomab(anti-EpCAM x anti-CD3) in patients after curative resection of a confirmed gastric adenocarcinoma compared with surgery alone
Investigation of the outcome of an adjuvant treatment with catumaxomab as compared to surgery alone in patients after curative resection of a gastric adenocarcinoma in order to gain more detailed info...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
1
2
Suivant